alexa Abstract | Targeting ROS for Cancer Therapy
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review Open Access


Reactive oxygen species (ROS) act as a second messenger in cell signaling and participate in a variety of biological processes in normal cells. Under normal physiological conditions, ROS are produced and then eliminated by ROS scavenging system to maintain cellular redox balance. Levels of ROS could change with endogenous or exogenous reasons, leading to DNA damage, oxidative stress and abnormal cell signaling. Reduction of ROS could lead to interruption of cell signaling, thus influence the cellular homeostasis. Cancer cell metabolism that often appear in the redox imbalance and oxidative stress, in the situation, antioxidant mechanism needs to balance this pressure, which has been the symbol of tumorigenesis [

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Jingwu Dong, Bin Liu, and Runzhi Zhu


Preventing cancer, Genomic, Cell signalling, Reactive oxygen species, Preventing cancer, Genomic, Cell signalling, Reactive oxygen species

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version